PTGX
Protagonist Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$145.50
−2.22%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
72.6x
EV/EBITDA
101.1x
Market Cap
$9.42B
MomentumView details →
1D Return
−2.22%
YTD Return
+66.87%
RSI (14)
49.4
ValuationView details →
P/E (Fwd)
72.6x
EV/EBITDA
101.1x
Market Cap
$9.42B
RSI (14)
49.4
MomentumView details →
1D Return
−2.22%
YTD Return
+66.87%
SummaryUpdated Jun 1, 2026
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a clinical-stage biopharmaceutical company founded in 2006 and headquartered in Newark, California. The company went public in August 2016 and specializes in discovering and developing peptide-based therapeutic drugs targeting hematology, blood disorders, and inflammatory diseases. Protagonist has evolved from a research-focused biotech startup into a company with multiple clinical-stage programs and strategic partnerships, including a significant collaboration with Janssen Biotech.
Similar companies
Latest newsMore news →
The U.S. Food and Drug Administration approved a first-of-its-kind drug from Takeda Pharmaceutical and Protagonist Therapeutics to treat a rare blood cancer, announced on Friday.7d agoProtagonist Therapeutics reported Q2 2026 earnings of $2.29 per share, beating the Zacks Consensus Estimate of $2.11 per share, compared to a loss of $0.55 per share a year ago.30d ago